On the other hand, anticancer treatments (chemotherapies, radiation therapy) trigger down-regulation of SphK1 activity in various cancer cell and animal models suggesting that SphK1 could act as a “sensor” to anticancer therapies particularly in prostate cancer [36], [37]. Here, SPHK1 is linked to prostate carcinoma.